TP53 in MDS and AML: Biological and clinical advances

Area of Science:

• Oncology
• Hematology
• Molecular Biology

Background:

• The TP53 tumor suppressor gene is frequently mutated in various cancers, including myeloid neoplasms.
• Multi-hit TP53 mutations are associated with poor prognosis in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS), as highlighted by the WHO-5 and ICC 2022 criteria.
• The diverse characteristics of TP53 mutations, such as variant allele frequency (VAF), copy number variations (CNVs), allelic status, karyotypes, and concurrent mutations, are critical areas of investigation.

Purpose of the Study:

• To explore the biological behaviors of TP53 mutations in myeloid neoplasms.
• To address the challenges in accurately predicting the prognosis of patients with TP53-mutated myeloid neoplasms.
• To highlight the need for effective treatment strategies for TP53-mutated myeloid neoplasms.

Main Methods:

• Extensive review and analysis of diverse TP53 mutation characteristics (types, VAF, CNVs, allelic status, karyotypes, concurrent mutations).
• Investigation into the biological roles of mutated TP53 in tumorigenesis.
• Assessment of current technological advancements in developing novel therapeutic targets and treatment strategies.

Main Results:

• TP53 mutations play a critical role in the tumorigenesis of myeloid neoplasms.
• Diverse characteristics of TP53 mutations significantly influence patient outcomes.
• Despite technological advances, predicting prognosis and effective treatment for TP53-mutated myeloid neoplasms remain difficult.

Conclusions:

• Accurate prognosis prediction for TP53-mutated myeloid neoplasms is challenging.
• There is a critical unmet need for effective therapeutic strategies for patients with TP53-mutated myeloid neoplasms.
• Further research into the biological mechanisms and therapeutic targeting of TP53 mutations is warranted.